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Asthma may affect 5-10% of the population in Western countries and is probably
underdiagnosed (I\4ortagy et al., 1986). Despite improved possibilities for therapy and
increased drug use morbidity and mortality are still increasing (Page, 1993). The social
and financial burden of the disease is therefore substantial.
Bronchial hyperreactivity (BHR) is a prominent feature of the disease. It is defined as an
increased reactivity of the airways to a wide range of physical, chenÍcal and
pharmacological stimuli. This "non-specific" bronchial hyperreactiviry is an important
determinant of the bronchial obstructive reactions that may develop after both allergenic
and non-allergenic stimulation of the airways. Bronchial hyperreactiviry may be induced
by a number of exogenous factors including exposition to airborne allergen and is almost
invariably associated with inflammation of the airways. Therefore, inflammation is
generally considered as an important causative factor of (allergen-induced) bronchial
hyperreactivity, although the exact mechanisms of inflammation-induced bronchial
hyperreactivity are still unclear. Several changes in the airways could be involved,
including an increased airway smooth muscle contractility, a reduction in airway calibre
and a change in neurogenic, humoral or paracrine control of the airways (chapter l).
For a critical evaluation of these possibilities anatomical, morphological and functional
aspects of the airways are described in chapter 2.
Allergen provocation of allergic asthmatics results in airways obsfiuction through the
release of bronchoconstrictive mediators released from mast cells. This early asthmatic
reaction (EAR) lasts l-2 hours and, in a number of individuals, is followed by a late
asthmatic response (LAR) which develops between 4-6 hours after allergen exposure and
may last for up to 24 h after the challenge. The LAR is characterized by an influx of
rnflammatory cells, predominantly eosinophils and neutrophils, into the airways, which is
most likely initiated by the release of chemotactic factors by rnast cells after allergen
exposure. These inflammatory cells are potentially important for the development of
allergen-induced BHR that may be observed before and after the late asthmatic response.
However, the causal relationships between allergen-induced early and late phase asthmatic
teactions, airway inflammation, and the development of BHR are largely unknown
(chapter 3).
The aim of the studies described in this thesis was to elucidate some of the mechanisms
rnvolved in the development of allergen-induced BHR. To study these mechanisms, ln
vivo as well as in viíro investigations of airway functioning and inflammation are
essential. For obvious reasons, most of these studies cannot be performed in human
asthmatics. Therefore an animal model is required for these investigations. Many different
animal models of allergic asthrna have been developed, including rats, guinea pigs,
nbbits, dogs, and sheep. For convenience, a small laboratory animal was preferred. Of
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these, the ovalbumin-sensitized guinea pig may be in favour because of the well-
documented allergic responses with respect to mediator release, early and late asthmatic
reactions and airway inflammation, that closely mimic the responses observed in human
asthmatics (chapter 4).
In order to investigate mechanisms of BHR in relation to the development of the LAR as
well as the effects of pharmacological treatÍnent upon these parameters, it was considered
necessaq/ to measure airway functions continuously for prolonged periods of time (24 h),
and also to be able to repeat these measurements a number of times during several weeks.
A thorough survey of available literature revealed that existing methods of airway function
measurement are generally based on either (whole)body-plethysmography, and/or on
invasive methods employing anesthesia. Since these methods did not meet our criteria we
developed a novel method for the measurement of airway functions in permanently
instrumented, conscious and unrestrained guinea pigs (chapter 5).
The technique utilizes a specially designed pneumotachograph or pitot nrbe that is placed
inside the trachea. The pneumotachograph consists of a stainless steel cylinder with
coaxial and perpendicular tubes attached to it, measuring the total and lateral pressure in
the trachea, respectively. Via air-frlled silicon tubes the pressures are fed into a
differential pressure transducer, yielding a pressure difference proportional to the airflow
inside the trachea. A small latex balloon was attached to a saline filled cannula and placed
inside the thoracic cavity to measure pleural pressure using a second pressure fansducer.
The tubings used for both devices were subcutaneously driven to the neck of the animal
and permanently atached. This enabled repeatable connection to the pressure transducers
without the animals being aware of the measurements taken.
The airflow and pleural pressure measurements enabled calculation of tidal volume,
dynamic compliance, and airway resistance, which were all in the range of values found
with conventional methods. In this study, a very good correlation was observed between
airway resistance and pleural pressure under normal as well as under obstructive
conditions. To facfitate the ease of experiments and to ease the surgical burden on the
animals, it was then decided to continue with sole pleural pressure measurement as an
index of airway obstruction (chap0er 5).
The sensitization and allergen provocation procedures applied to experimental animals
may greatly determine the development of allergen-induced early and late phase Íeactiotls
and BHR. Based on data available in literature our guinea pigs were initially sensitized h
ovalbumin using two different adjuvants: Freunds Complete Adjuvant (FCA) to facilinr
production of IgG,-antibodies, and aluminum hydroxide (AI(OH)3) to facilitate IgE levels,
In both groups a signif,rcant airway obstruction was observed immediately after expoun
to a low dose of antigen without prophylactic treatÍnent with antihistaminics to preveil
development of fatal anaphylaxis. The EAR lasted approximately 4 hours and uru
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pressure curve between 8 and 24 h after allergen exposure. Bronchial reactivity to
histamine inhalation was measured as the provocation concentration causing a 100 %
increase in pleural pressure compared to baseline (PC,oo). A ratio in PCr'o prelpost
allergen exposure was determined after the EAR (6 h) as well as after the LAR (24 h).
In the IgG as well as the IgE animals allergen exposure resulted in a marked increase in
bronchial reactivity to inhaled histamine at 6 h, which was lower, but still significantly
increased at 24 h after provocation. Both in a qualitative and in a quantitative sense, the
eady and late increases in bronchial reactivity were very comparable to that observed in
allergic asthmatics. In asthmatics, however, allergen-induced BHR may be sustained for
several days or even weeks. Since IgE antibodies are predominantly involved in human
asthma, the IgE animals were subjected to different allergen exposure protocols to
investigate whether the late BHR could be enhanced and/or sustained. A second allergen
provocation, 7 days after the fust one, yielded a similar development of BHR. Daily
repeated allergen provocations for four days resulted in a decreased development of BHR,
despite a daily increase in allergen concentration necessary to reach identical early
bronchospasm. In a final attempt to enhance late BHR, IgE-animals were resensitized
twice (boostered) and subsequently exposed to allergen twice a week for 5 weeks. Since
this protocol also failed to induce sustained BHR, it was concluded that this guinea pig
model is an excellent model for early and late, but not for sustained BHR (chapter 6).
Approximately 7O% of the animals developed a LAR after the EAR. When comparing
these dual responding animals with single early responders with respect to the
development of BHR, a clear difference was observed. While dual responders
demonstrated a significant increase in the reactivity of the airways, before as well as after
the LAR, such an increase was absent in single early responders. The presence of BHR
before the LAR in dual responders might indicate that this early BHR may contribute to
or even cause the development of the LAR. However, no significant correlation was
observed between the BHR at 6 h and the severity of the LAR. In addition, in 2 animals
responding to allergen exposure with only a late reaction, an increase in bronchial
reactivity before the LAR was absent, indicating that, although the presence of BHR may
increase the severity of the LAR, these two feahrres of asthma are causally unrelated and
merely triggered by the same event, i.e. allergen exposure to sensitized animals. This
conclusion is supported by the marked correlation between the initial increase in pleural
pressure during the EAR and the early as well as late BHR, indicating that early events
during the EAR may determine the subsequent development of BHR.
The observation that the early BHR is greatr;Í in magnitude that the late BHR, in
combination with the absence of late BHR in the single late responders, suggests that late
BHR is not caused by the LAR as was currently believed, but merely a remainder of ttre
early BHR. As in human studies, this hypothesis is confirmed by the absence of a
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significant correlation between the severity of the LAR and the degree of BHR after the
LAR.
Since numerous studies have indicated a close association between airway inflammation
and BHR in asthmatics, it is generally accepted that inflammatory cells and their
mediators play an important role in the allergen-induced LAR as well as BHR. The
number of eosinophils and neutrophils in the bronchoalveolar lavage (BAl)-fluid was
markedly enhanced after the EAR as well as the LAR, similar to that observed in
asthmatic patients. However, a dissociation was observed between the time course of
eosinophil influx, which was maximal at 24 h after allergen exposure, and the
development of BHR, which was maximal at 6 h (chapter 7).
A possible explanation for this dissociation may be the activation state of the infiltrated
eosinophils. Indeed, using eosinophil peroxidase @PO) activity in the BAl--fluid as a
marker for eosinophil activation, an increase in activation state was observed at 6 h after
allergen exposure, while EPO-activify was not further increased at 24 h. Surprisingly, the
EPO-activity was closely correlated with BHR at 24 h, but not at 6 h after allergen
exposure. It is therefore likely that additional mechanisms contribute to the early BHR.
Using the same guinea pig model, a dysfunction of autoinhibitory muscarinic Mr-receptors
has recently been observed in our laboratory, contributing to the BHR at 6 h but notat24
h after allergen exposure (Ten Berge etal.,1992). This dysfunction is presumably caused
by allosteric antagonism of major basic protein, another positively charged eosinophil
derived protein, on the Mr-receptor (Jacoby et al., 1993) (chapter 8).
Since the onset of allergen-induced bronchospasm as well as its recovery by
bronchodilators may occur very rapidly, airway smooth muscle contraction is clearly
implicated in the pathogenesis of allergic asthma. Therefore, changes in airway smooth
muscle function could contribute to allergen-induced BHR. Contractile and relaxant
responses of tracheal smooth muscle preparations from allergen-challenged guinea pigs
were investigated in vitro. The sensitivity and maximal response to methacholine and
histamine were not altered at 6 h and 24 h aftBr a single allergen exposure as well as at 24
h after four daily repeated provocations. By contrast, a small but progressive loss of B-
adrenoceptor sensitivity, but not of maximal relaxation, was observed after the allergen
provocation, which was parallelled by an increase in the number of eosinophils in the
BAl-fluid. These results suggest that (mediators from) eosinophils may be involved in the
altered B-adrenoceptor sensitivity. Since the time course of B-adrenoceptor dysfunction,
increasing in time, was strongly dissociated from the development of BHR, being maximal
shortly after allergen exposure, this reduced B-adrenoceptor function is not regarded as
principally important in the development of increased airway reactivity. Its relevance for
the use of bronchodilator treatment, however, is unknown (chapter 9).
Since allergen-induced EAR and LAR, as well as early and late BHR and airway














































































repeated with a weekly interval, we were able to study the effects of various
pharmacological compounds on these features of asthma. Since we found that the
development of the LAR as well as BHR in this model appeared to be critically dependent
upon the initial degree of airway obstruction during the EAR, which is predominantly
caused by the release of histamine, we investigated the effect of the selective H,-
antagonist mepyrarnine on allergen-induced asthmatic reactions, BHR and inflammatory
cell infiltration (chapter l0). We observed that inhalation of mepyramine I h before
allergen challenge caused a significant reduction in the severity of the EAR which can
easily be explained by H,-antagonisrn. In addition, we found that mepyramine caused a
significant reduction in the magnitude of the LAR and prevented the early as well as the
late BHR to both histamine and metltacholine. Because in control animals rnepyramine
hardly reduced histamine-induced bronchoconstriction at 7 h after application, it is
unlikely that the inhibition of the LAR as well as the early and late BHR to histamine and
methacholine proceed via a direct effect of the anti-histaminic on airway smooth muscle.
The effects of mepyramine on both the LAR and BHR could, however be due to a
reduction of airway inflammation , as indicated by a reduced number of infiltrated cells in
the BAL-fluid. The results of this srudy turther indicate that proVactic aCnjniitraíron oí
antihistaminjcs to prgrgx; anap|ylaxrs rn allergen-challenged guinea pigs, as described
previously, will reduce the development of the LAR and BHR in these animals.
The possible contribution of an enhanced vagal reflex mechanism to the severity of BHR
was investigated using the anticholinergic compound ipratropium bromide to prevent
cholinergic bronchoconstriction. A contribution of this vagal reflex rnechanism was
indicated by the observation that BHR to histamine inhalation was higher than to
methacholine, the latter inducing only direct airway smooth muscle contraction. The
inhibition of allergen-induced early BHR to histamine by ipratropium, rn a concentration
which had no effect on histamine-induced bronchoconstriction in control animals, clearly
indicated that the vagal reflex bronchoconstriction is increased after allergen exposure.
Possible mechanisms for the enhanced vagal reflex bronchoconstriction may include
disruption of the airway epithelium by cytotoxic cationic proteins released from
eosin,lphils, thereby facilitating the access of histamine to sensory nerve endings as well
as a dysfunction of the autoinhibitory muscarinic Mr-receptors, possibly by the same
cationic proteins. A lO-fold increase of the ipratropium concentration, however, did not
further educe bronchial reactivity to histamine, indicating that other mechanisms also
contribute to rhe early BHR (chapter I 1).
i 
Ahwav inflammation is clearly involved in the pathogenesis of asthma. Nonetheless,
symptomatic bronchodilator therapy is still widely applied in asthma and this may underlie
lhe ever increasing morbidity and mortality frorn this disease.
ldeally, bronchodilator therapy should also express anti-inflammatory actlvity, beyond
ma$ cell stabilization. Current evidence suggests that phosphodiesterase (pDE) inhibitors
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may combine the bronchorelaxant, mast cell stabilizing, and anti-inflammatory actions
necessary for adequate treatÍnent. Especially the newer type IV-selective PDE-inhibitors
may be useful because they specifically inhibit type IV-PDE present in airway smooth
muscle as well as in inflammatory cells and are likely to express reduced side-effects.
The non-selective PDE-inhibitor theophylline, as well as the type IV-selective PDE-
inhibitors rolipram and ORG 20247 were used in concentrations that did not affect the
magnitude of the early and late phase response. When administered t h before allergen
provocation all three compounds, at these concentrations, significantly reduced allergen-
induced early and late BHR to a similar degree. In addition, BAl-studies indicated a
selective inhibition of airway inflammation by the PDE-inhibitors. Thus, theophylline
significantly reduced the allergen-induced influx of eosinophils, neutrophils, and
macrophages. Rolipram reduced the number of neutrophils and lymphocytes, while the
number of eosinophils and macrophages were reduced by ORG 20241 . The results suggest
that low doses of the PDE-inhibitors markedly reduce allergen-induced development of
BHR by inhibition of inflammatory cell infiltration. Moreover, these results indicate that
BHR is not due to the actions of a singular cell type but the result of a carefully
orchestrated series of events, involving several cell types.
In conclusion, allergen-induced early and late phase asthmatic responses, early and late
phase bronchial hyperreactivity and airway inflammation in this newly developed guinea
pig model of allergic asthma are strikingly similar to those observed in human asthma.
The development of BHR and LAR appear to be principally independent, although the
eady BHR.may enhance the severity of the LAR. Both features of allergic asthma are
initiated during the early phase of the allergic cascade. Histamine is a very important
mediator in the EAR, possibly through a facilitatory action on the infiltration of
inflammatory cells into the airways. The higher BHR for histamine, compared to that for
methacholine, suggests a contribution of a cholinergic reflex mechanism. Using
ipratropium bromide it was observed that sensory nerve endings, which activate the vagal
reflex bronchoconstriction, are indeed more sensitive to histamine after allergen
provocation and thus may contribute to the early BHR. Activation of infiltrated
eosinophils may contribute to this enhanced sensitivity by the release of cytotoxic
mediators, which can damage the epithelial lining. The markedly increased EPo-activity
in the BAl-fluid supports this hypothesis. Changes in airway smooth muscle function do
not substantially contribute to allergen-induced BHR, although a small time-dependent
decrease in B-adrenoceptor sensitivity was observed after allergen provocation.
The importance of inflammatory cells for the development of allergen-induced BÍlR is
also supported by the effects of mepyramine and the phosphodiesterase-inhibitors
theophylline, rolipram and ORG 20241 , which more or less selectively inhibited theinflux
of inflammatory cells into the airways and therewith reduced BHR.
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